Last reviewed · How we verify
Sandostatin ® injection
Sandostatin (octreotide) is a somatostatin analog that binds to somatostatin receptors on neuroendocrine cells to inhibit the secretion of growth hormone, insulin, and other hormones.
Sandostatin (octreotide) is a somatostatin analog that binds to somatostatin receptors on neuroendocrine cells to inhibit the secretion of growth hormone, insulin, and other hormones. Used for Acromegaly (growth hormone-secreting pituitary adenoma), Variceal bleeding in portal hypertension, Carcinoid syndrome.
At a glance
| Generic name | Sandostatin ® injection |
|---|---|
| Also known as | Octreotide LAR, Octreotide, Octreo, Lanreotide |
| Sponsor | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
| Drug class | Somatostatin analog |
| Target | Somatostatin receptors (SSTR2, SSTR5) |
| Modality | Small molecule |
| Therapeutic area | Oncology; Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Octreotide mimics the natural hormone somatostatin by binding to somatostatin receptors (particularly SSTR2 and SSTR5) on neuroendocrine tumor cells and normal endocrine tissues. This binding suppresses the release of excessive hormones and growth factors, reducing symptoms associated with hormone-secreting tumors and controlling hormone-related complications. It also has anti-proliferative effects on some neuroendocrine tumors.
Approved indications
- Acromegaly (growth hormone-secreting pituitary adenoma)
- Variceal bleeding in portal hypertension
- Carcinoid syndrome
- VIPoma (vasoactive intestinal peptide-secreting tumor)
- Gastrinoma
- Neuroendocrine tumors
Common side effects
- Abdominal pain or discomfort
- Diarrhea
- Nausea
- Headache
- Hyperglycemia or hypoglycemia
- Gallstone formation (cholelithiasis)
- Injection site pain or reaction
Key clinical trials
- Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (PHASE3)
- 177Lu-DOTATATE for Recurrent Meningioma (PHASE2)
- Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (PHASE3)
- Real-world Study on Adjuvant Octreotide Therapy in pNETs (NA)
- A Single-dose Study of Octreotide Injection in Healthy Adult Subjects (PHASE1)
- Ghrelin Suppression by Octreotide in Prader-Willi (NA)
- Evaluation of Impact of Sandostatin® Injection Before Axillary Clearance on Lymphocele Formation (NA)
- Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sandostatin ® injection CI brief — competitive landscape report
- Sandostatin ® injection updates RSS · CI watch RSS
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. portfolio CI